Nuvalent, Inc. Stock News

CAMBRIDGE, Mass., March 5, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase

Nuvalent, Inc. expects final results from the phase 1 ARROS-1 study, using NVL-520 for the treatment of patients with ROS-1 positive non-small cell lung cancer, in 2024 at a medical meeting. Final res

CAMBRIDGE, Mass. , Dec. 21, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kina

Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms.

The biotech announced a secondary share flotation. It will sell over 5 million shares of its common stock in a public offering.

Nuvalent announced favorable preliminary data from a phase 1 trial indicating its drug NVL-655 was well tolerated with mild adverse events. It's still early, but management is encouraged by the data.

Nuvalent (NUVL) surges 36% on encouraging preliminary results from the phase I dose-escalation portion of its early-mid-stage development program for NVL-655 to treat advanced ALK-positive NSCLC.

Nuvalent, Inc. stock gained 36% and reached an all-time high of $58 per share yesterday, with a market cap valuation of $3.3bn. The biotech company is focused on developing targeted therapies for canc

Nuvalent is a clinical-stage biotech. The company said its therapy showed effectiveness and a strong safety profile in its phase 1/2 trial to treat ALK-positive non-small cell lung cancer.

Company plans to host a conference call on October 13, 2023 CAMBRIDGE, Mass. , Sept. 18, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creat

CAMBRIDGE, Mass. , Aug. 31, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinas

Deerfield Management Company, L.P. (Series C), a renowned investment firm, recently made a significant addition to its portfolio.

CAMBRIDGE, Mass. , Aug. 1, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase

If you are looking for stocks that are well positioned to maintain their recent uptrend, Nuvalent, Inc. (NUVL) could be a great choice. It is one of the several stocks that passed through our "Recent

Nuvalent, Inc. (NUVL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through